We report a series
previous history of psychosis. In eight patients the psychosis occurred following a change in the habitual pattern of seizure activity; in four it developed after a period of seizure freedom followed by a cluster of seizures, and in the other four patients an alternating psychosis was observed. In five patients there was no clear relationship to seizure pattern. Another patient developed psychosis after taking an overdose of between eight and 12 g of vigabatrin. A further three patients, who developed psychosis following vigabatrin withdrawal, were not included in this series. The mean dose at onset of the psychosis (excluding the patient who took an overdose) was 2580 mg, and the period from initiation of therapy to the onset of psychosis varied from five days to 32 weeks (and occurred 24 hours after the overdose of vigabatrin). In all cases the psychosis resolved, but necessitated the withdrawal of vigabatrin, except in the single patient who took the overdose. The mechanism of this behaviour change is unclear, but in some instances may reflect vigabatrin's powerful anti-epileptic action. This is clearly not the case for all patients. Vigabatrin should be started with caution in patients with severe epilepsy, particularly in the presence of a previous history of psychosis, and such patients should be carefully monitored.
Vigabatrin, a new anti-epileptic drug, is an irreversible inhibitor of gamma-aminobutyric acid aminotransferase (GABA-T), the main catabolic enzyme of the cerebral inhibitory neurotransmitter GABA. It leads to a rise in GABA concentrations in cerebrospinal fluid and in the brainl" which is believed to be the basis of its anti-epileptic action. The efficacy of vigabatrin as a new anti-epileptic drug has been established in controlled studies and it has been shown to reduce partial and generalised tonic-clonic seizures.''0 Vigabatrin has recently been registered in the United Kingdom for use as an anti-epileptic drug in refractory epilepsy.
The side effect profile of vigabatrin is not dissimilar to other anticonvulsants, especially in the early phases of treatment, and to date no particular long term hazards have been identified. Reversible intra-myelinic oedema has been described in early toxicity studies in experimental animals. This was seen in rodents and beagles, but has not been seen in primates or humans.""3
Behavioural changes associated with the initiation of vigabatrin therapy have been reported. Behaviour has been variously documented as being improved'4 or deteriorating."5 In investigations, however, using standardised and validated rating scales, evidence for a consistent effect on affective symptoms is lacking. '6 More severe behavioural problems reported, sufficient in some cases to lead to withdrawal of the drug, include severe agitation7 18 and psychosis.'920 We report here a series of 14 cases of psychosis which occurred following the prescription of vigabatrin, some of which were noted during a clinical trial of the drug reported elsewhere.21 22 Patients and methods During the past four years, we Nine patients had no previous history of psychosis, although two of these patients had a long history of behavioural disorders and one had a previous diagnosis of anorexia nervosa.
Two patients had had an earlier psychotic episode when clobazam was prescribed and the remaining three patients had an earlier history of interictal psychosis not associated with seizures or drugs.
The pattern of seizures in eight of these patients was of particular interest, with four patients falling into each of two readily identifiable patterns. In the first (pattern 1), patients (3, 8, 9 , and 10) became seizure free fairly soon, or virtually so, following the introduction of vigabatrin, only to develop a cluster ofseizures, following which the psychosis erupted (in all within five days and in most within 48 hours of the cluster). The clinical diagnosis in three was of a schizophrenic psychosis with auditory and visual hallucinations and religious delusions. The fourth developed a twilight state with visual hallucinations and delusions. In this pattern, in all patients the period of seizure freedom was unusually long, and some patients' notes contained comments such as "this is the longest ever free of attacks", identifying the change of pattern. In one case EEG recordings were obtained after the seizure cluster when the patient was psychotic. The record had normalised in contrast to recordings taken in the pre-treatment, pre-psychotic state (fig 1) . In patients 3 and 9, the psychosis resolved on halving the dose of vigabatrin, only to recur after a period of five weeks to four months without a seizure cluster, necessitating complete withdrawal of the drug.
In the other pattern (pattern 2), the patients became seizure free, and developed the psychosis some time after the onset of the seizure remission. The time elapsing varied from ten days to six weeks. This pattern was seen in four cases (patients 6, 7, 11 and 14) . Three of these patients had a schizophrenic-like psychosis, and the fourth had an organic psychosis. EEG records in two patients with pattern 2 show some evidence of forced normalisation23 24 (one example is shown in fig 2) . This is the change from a patient's usual abnormal interictal EEG, during the non-psychotic state, to a normal or near normal EEG during the psychosis.
It is worth noting that two of these patients had had an earlier psychotic episode when their seizures were treated and remitted in a similar way. Both (patients 6 and 11) were then prescribed clobazam, although at the time patient 11 also had phenytoin toxicity. Patient 14 Psychosis in these patients in association with GVG has followed a cluster of seizures (post-ictal psychosis-pattern 1), a period of seizure freedom (altemating psychosispattem 2), withdrawal of anti-epileptic drugs, drug overdose, or in some cases occurred independently of all these factors.
In pattern 1 (4 cases), patients had suppression of their seizures following drug initiation, and then suddenly had a burst or cluster of seizures (representing a change in pattem) which was followed by the psychosis. Psychotic episodes were short lasting, and resolved with reduction or withdrawal of the vigabatrin. In the two patients who had the dose reduced, however, there was a subsequent recurrence of the psychosis (without a seizure cluster), necessitating the complete withdrawal of the drug. In pattem 2 (4 cases), an altemating psychosis occurred with EEG evidence in two (patients 6 and 14) of forced normalisation (fig 2) . The remaining six cases did not fit clearly into either ofthese two patterns. Two ofthese patients had had a previous history of psychosis, however, and a third developed psychosis after an overdose ofvigabatrin. In addition to these 14 cases, three further patients were seen who developed psychosis on withdrawal of vigabatrin.
The literature on post-ictal psychosis is limited, and such states, while being common in practice, are not well documented. In the largest series, that of Levin,25 clinical features similar to our cases in pattern 1 were noted, and it was reported that the onset could be up to seven days after the seizures. Two or more attacks usually preceded the psychosis. In the more recent series of Logsdaile and Toone,26 clusters were again a frequent herald to the psychosis, and there was often a lucid interval of several (up to six) days before the psychosis appeared. Further work in this area is urgently required.
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result from an alteration in seizure activity. Furthermore, it is common clinical experience that epileptic psychosis is more frequent in patients with severe epilepsy; all patients in this series had a severe and intractable seizure disorder and over one third had a previous history of psychosis. Whatever the mechanism of the psychosis, and the relationship between this and the prescription of vigabatrin, we would urge caution when starting vigabatrin, particularly in patients with a previous history of psychosis or with severe chronic epilepsy.
Other behaviour disturbances were also seen in some of our patients, including agitation, confusion, hyperactivity, stupor and depression and certainly in our series and others, behaviour changes were the most common important side effect of this anti-epileptic drug.
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